CD163 and neoplasm: Most importantly, the combined approaches of Bevacizumab and ipilimumab might synergistically increase the infiltration of CD163+ dendritic macrophages and CD8+ T Cells via tumor vasculatures (Hodi et al., 2014; Ott et al., 2015).